– FRANCE, Nantes – OSE Immunotherapeutics (EPA:OSE), today announces that Gérard Tardy has been appointed as Director and new Chairman of the Board effective 3 January. Mr. Tardy is a long-time healthcare investor, and is currently a member of the Investment Committee of Mérieux Développement, a specialized healthcare fund.
Mr. Tardy will replace Emile Loria, founder of OSE, who, following more than 30 years in key functions in the biotechnology industry, has resigned for personal reasons. The co-optation and appointment of Mr. Tardy will be subject to shareholder approval at the Annual General Meeting. Separately, the resignation for personal reasons of another Director, Guy Châtelain, also will become effective during the next AGM and the Board thanks him warmly for his contribution to their work.
“On behalf of all the Directors and the whole OSE team, I thank Emile Loria for his significant contribution and strong commitment to the Company’s growth strategy. We are at a pivotal time for the company with Tedopi® resuming Phase 3 trial in lung cancer, targeting patients for which checkpoint inhibitors have failed. This is a great opportunity in a very promising market with a strong medical need and no available treatments for these patients in immunological escape,” said Dominique Costantini, CEO and Director of OSE Immunotherapeutics.
“We are delighted to welcome Gérard Tardy, whose rich international experience, both in finance and healthcare, fits perfectly with our growth strategy as we are developing a new generation of immunotherapies highly attractive for the pharmaceutical industry: a myeloid checkpoint inhibitor, OSE-172, an immunomodulator targeting the IL7 receptor, OSE-127 and the CD28 antagonist, FR104. In fact, the latter two products are already part of license agreements with pharmaceutical companies potentially totalling more than €400M,” concluded Dominique Costantini.
Mr. Tardy stated, “I thank the Board for placing their trust in me at a moment of significant opportunity, as cancer and autoimmune disease immunotherapy represents a therapeutic transformation. The expertise developed by OSE with immunity agonists and antagonists positions the company very well for future success in the field, and I look forward to working closely with the management team to increase its visibility globally.”
“I am very proud to have contributed to the creation of OSE, its initial growth phase and current position as a leader in the development of immunotherapies. I wish Gérard success in his new role, and look forward to future innovations from OSE”, said Mr. Loria.
Based in London, Mr. Tardy has significant experience in private equity in Europe. Previously, he created and managed two private equity funds in Paris, Cititcorp Venture Capital and Schroder Ventures. In 1999, Mr. Tardy formed his own investment company, Sitka Limited, in London, through which he has invested in several healthcare companies. Mr. Tardy currently serves on the Board of multiple healthcare companies in Europe and Asia. He graduated from HEC in Paris.
ABOUT OSE Immunotherapeutics
Our ambition is to become a world leader in activation and regulation immunotherapies:
OSE Immunotherapeutics is a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, autoimmune diseases and transplantation. The company has several scientific and technological platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases. Its first-in-class clinical portfolio offers a diversified risk profile.
For more information : http://www.ose-immuno.com/en
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
